Dr. Xin An 安欣
Chief Physician
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical oncology and anticancer drug research, focusing on chemotherapy, endocrine therapy, and targeted therapy for breast cancer and urological tumors.
Dr. An holds a PhD in clinical oncology and has worked in the Department of Medical Oncology at Sun Yat-sen University Cancer Center since 2008. Dr. An was a visiting scholar at Memorial Sloan Kettering Cancer Center from June 2009 to June 2010 and at The Ohio State University from February 2016 to January 2017.
Professional roles
- Member, Young Breast Cancer Committee, Chinese Medical Association
- Secretary, Youth Committee of Oncology Branch, Guangdong Medical Association
- Member, Breast Specialist Branch, Guangdong Physician Association
- Member, Urogenital Tumor Professional Committee, Guangdong Anti-Cancer Association
Name order: in Chinese the family name comes first (An Xin). Papers usually list the name as Xin An or An X.
Selected publications
99 papers on PubMed matched by name and affiliation; 18 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Immunother Cancer, 2026 (senior author): Sintilimab plus eribulin and carboplatin in patients with metastatic triple-negative breast cancer (SECURE): a phase II, multicenter trial. PubMed 42919625
- Cancer Med, 2026 (senior author): Germline Pathogenic Variants in HER2-Positive Breast Cancer: Spectrum and Clinical Implications in a High-Risk Chinese Cohort. PubMed 42141527
- NPJ Breast Cancer, 2025 (senior author): Real-world outcomes of trastuzumab deruxtecan in HR-negative HER2-low metastatic breast cancer. PubMed 41203648
- Cancer Sci, 2025 (senior author): Efficacy and Safety of T-DXd in HER2+ and Low/Zero Metastatic BCBM: A Retrospective Multicenter Real-World Study. PubMed 40936283
- Front Immunol, 2025 (senior author): HER2-positive breast cancer with invasive micropapillary carcinoma component shows immunosuppressive microenvironment and resistance to neoadjuvant therapy. PubMed 40821778
- Eur J Cancer, 2025 (senior author): Olanzapine combined with standard antiemetics for the prevention of nausea and vomiting in patients with germ cell tumor undergoing a 5-day cisplatin-based chemotherapy (NAVIGATE study): A phase III crossover trial. PubMed 40311506
- Cancer Cell, 2025 (first author): Neoadjuvant toripalimab plus nimotuzumab combined with taxol-based chemotherapy in locally advanced penile squamous cell carcinoma. PubMed 40215977
- BMC Cancer, 2025 (senior author): RC48-ADC monotherapy or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma with HER2 low and null expression: a multicenter, real-world, retrospective study. PubMed 40307755
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion